Differential effects of antibodies to Lyt-2 and L3T4 on cytolysis by cloned, Ia-restricted T cells expressing both proteins.
Open Access
- 15 July 1987
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 139 (2) , 380-384
- https://doi.org/10.4049/jimmunol.139.2.380
Abstract
Cloned T cell lines specific for the antigen ovalbumin (OVA) in the context of self I-A or I-E class II MHC-encoded molecules were found to express equivalent levels of the Lyt-2 and L3T4 surface molecules by FACS analysis. Functionally, these cloned T cell lines will kill OVA-pulsed, class II MHC-bearing B lymphoma cells. This system allowed us to examine the relative contribution of the Lyt-2 and L3T4 molecules to recognition of antigen in the context of self class II MHC molecules. We find that anti-L3T4 is 25- to 100-fold more potent at inhibiting cytotoxicity by these cloned lines than is anti-Lyt-2, where potency is calculated as the ratio of the concentration needed for inhibition divided by the concentration needed for binding. Both antibodies can completely inhibit cytotoxicity. These results suggest that the accessory molecules Lyt-2 and L3T4 can play two different roles in antigen:MHC recognition. In class II MHC recognition, L3T4 plays a dominant role, highly sensitive to inhibition by anti-L3T4. By contrast, Lyt-2 plays a minor yet important role in the cell interaction, perhaps by adhesion strengthening. Previous analysis in several laboratories supports the concept that the ligand for L3T4 is class II MHC, whereas the ligand for Lyt-2 is class I MHC. The present results are consistent with the hypothesis that these molecules are actually part of the T cell antigen:MHC recognition complex, and play an important role in the class of MHC molecule recognized by a T cell alpha:beta heterodimeric receptor. As such, they are not accessory proteins, but a direct part of the recognition apparatus, and the term accessory protein may apply only in those cases in which the specificity of the T cell receptor is for a different class of MHC than that normally associated with the L3T4 or Lyt-2 molecule.This publication has 16 references indexed in Scilit:
- Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin 1 is required for the expression of receptors for interleukin 2.The Journal of Immunology, 1984
- The expression of I-Ed molecules in F1 hybrid mice detected with antigen-specific, I-Ed-restricted cloned T-cell linesImmunogenetics, 1984
- The role of L3T4 in recognition of Ia by a cytotoxic, H-2Dd-specific T cell hybridoma.The Journal of Experimental Medicine, 1984
- ANTIGEN-DEPENDENT SELECTION OF B-LYMPHOMA CELLS VARYING IN IA DENSITY BY CLONED ANTIGEN-SPECIFIC L3T4A + T-CELLS - A POSSIBLE INVITRO MODEL FOR B-CELL ADAPTIVE DIFFERENTIATION1984
- Cloned helper T cells can kill B lymphoma cells in the presence of specific antigen: Ia restriction and cognate vs. noncognate interactions in cytolysisEuropean Journal of Immunology, 1984
- Evidence implicating L3T4 in class II MHC antigen reactivity; monoclonal antibody GK1.5 (anti-L3T4a) blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines.The Journal of Immunology, 1983
- Both a monoclonal antibody and antisera specific for determinants unique to individual cloned helper T cell lines can substitute for antigen and antigen-presenting cells in the activation of T cells.The Journal of Experimental Medicine, 1983
- Functional activities of antibodies against brain‐associated T cell antigens II. Stimulation of T cell‐induced B cell proliferationEuropean Journal of Immunology, 1982
- Significance of Lyt phenotypes: Lyt2 antibodies block activities of T cells that recognize class 1 major histocompatibility complex antigens regardless of their function.Proceedings of the National Academy of Sciences, 1981
- Establishment and Characterization of BALB/c Lymphoma Lines with B Cell PropertiesThe Journal of Immunology, 1979